BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24445288)

  • 1. Just caring: assessing the ethical and economic costs of personalized medicine.
    Fleck LM
    Urol Oncol; 2014 Feb; 32(2):202-6. PubMed ID: 24445288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices.
    Fleck LM
    N Biotechnol; 2012 Sep; 29(6):757-68. PubMed ID: 22433081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine: medicine for the privileged?
    Helft PR
    Oncology (Williston Park); 2012 Sep; 26(9):814. PubMed ID: 23061334
    [No Abstract]   [Full Text] [Related]  

  • 4. [PERSONALIZED MEDICINE : PHARMACOECONOMIC ASPECTS].
    Oruyère O; Reginster JY; Ethgen O
    Rev Med Liege; 2015; 70(5-6):339-42. PubMed ID: 26285463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
    O'Donnell JC
    Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Era of personalized medicine may herald end of soaring cancer costs.
    Keogh B
    J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
    [No Abstract]   [Full Text] [Related]  

  • 8. Personalized medicine policy challenges: measuring clinical utility at point of care.
    van Rooij T; Wilson DM; Marsh S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Just caring: defining a basic benefit package.
    Fleck LM
    J Med Philos; 2011 Dec; 36(6):589-611. PubMed ID: 22166261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of genomic medicine in a health care delivery system: a value proposition?
    Wade JE; Ledbetter DH; Williams MS
    Am J Med Genet C Semin Med Genet; 2014 Mar; 166C(1):112-6. PubMed ID: 24619641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics: Personalized drugs should cut care costs.
    Malik NN
    Nature; 2012 May; 485(7400):582. PubMed ID: 22660309
    [No Abstract]   [Full Text] [Related]  

  • 13. The 2010 Health Care Reform Act: a potential opportunity to advance cancer research by taking cancer personally.
    Dalton WS; Sullivan DM; Yeatman TJ; Fenstermacher DA
    Clin Cancer Res; 2010 Dec; 16(24):5987-96. PubMed ID: 21169252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
    Frueh FW
    Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical and health economic challenges of personalized medicine].
    Brüggenjürgen B; Kornbluth L; Ferrara JV; Willich SN
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):710-4. PubMed ID: 22526860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making personalized medicine more affordable.
    Aronson N
    Ann N Y Acad Sci; 2015 Jun; 1346(1):81-9. PubMed ID: 25728478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whether it is personalized, precision, or mechanistic medicine--- the clinical laboratory has a role.
    Kavsak PA
    Clin Biochem; 2012 Apr; 45(6):384. PubMed ID: 22424084
    [No Abstract]   [Full Text] [Related]  

  • 18. Trends and issues in oncology costs.
    Scalo JF; Rascati KL
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):35-44. PubMed ID: 24328809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ethical framing of personalized medicine.
    Joly Y; Saulnier KM; Osien G; Knoppers BM
    Curr Opin Allergy Clin Immunol; 2014 Oct; 14(5):404-8. PubMed ID: 25054830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of cancer care in the UK.
    Bosanquet N; Sikora K
    Lancet Oncol; 2004 Sep; 5(9):568-74. PubMed ID: 15337487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.